Under terms of the agreement, Eurand will manufacture Lamictal ODT exclusively, and may have certain rights to commercialize it outside the US. Eurand will receive an undisclosed milestone payment upon launch, revenue for manufacturing Lamictal ODT tablets for GSK, royalties on net sales of the product and milestone payments in connection with Lamictal ODT achieving predetermined sales levels in the U.S. marketplace. Granulation, encapsulation Eurand's proprietary Advatab technology employs granulation and tabletting technology to produce the ODT form, which can be taken by the patient with our without water. The Microcaps encapsulation technology coats drug particles to mask the drug's taste while allowing it to dissolves in the stomach.